Rhopressa

Manufacturing · United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

United States

Revenue

$6.9 Million

Industry

Manufacturing Pharmaceuticals
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1

About Rhopressa

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration. The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% ofRead more
Rhopressa's Social MediaPopular SearchesRhopressaAerie Pharmaceuticals IncSIC Code 28,283NAICS Code 32,325Show more

Is Rhopressa your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Rhopressa

Compare insights from companies similar to Rhopressa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Rhopressa

$6.9M
11-50
Private
-
2005
N/A
$5.1M
11-50
Private
$24.6M
2004
CB
Carolynne BornhutterTraining Director, Human Resources
<$5M
11-50
Private
-
-
WM
William McVicarExecutive Vice President & Scientific Chief & Officer
<$5M
11-50
Private
-
-
N/A
<$5M
11-50
Private
-
-
N/A
<$5M
1-10
Private
<$5M
1993
HL
Heather LapusnakOffice Manager
<$5M
11-50
Private
-
1999
SS
Sandy StaleyManager, Laboratory
Illustration of an envelope

Rhopressa Tech Stack

Rhopressa News & Media

Read more news

Top Manufacturing Companies

Frequently Asked Questions Regarding Rhopressa

What is Rhopressa's official website?
Rhopressa's official website is www.rhopressa.com
What is Rhopressa's Revenue?
Rhopressa's revenue is $6.9 Million
What is Rhopressa's SIC code?
Rhopressa's SIC: 28,283
What is Rhopressa's NAICS code?
Rhopressa's NAICS: 32,325
How many employees does Rhopressa have?
Rhopressa has 11-50 employees
What industry does Rhopressa belong to?
Rhopressa is in the industry of: Manufacturing, Pharmaceuticals
What is Rhopressa competition?
Rhopressa top competitors include: Dompé, BromSite, Inotek Pharmaceuticals, Insite Vision
What technology does Rhopressa use?
Some of the popular technologies that Rhopressa uses are: F5 Silverline DDoS Protection, Network Solutions SSL Certificates, The USERTRUST Network, Web.com Website hosting
What does Rhopressa do?

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Contact Lenses: Contact lenses... should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration. The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients. The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment. To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The recommended dosage is one drop in the affected eye(s) once daily in the evening. Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Contact Lenses: Contact lenses should be removed prior to ...Read More

What are Rhopressa social media links?
Rhopressa Linkedin page Rhopressa Twitter page
Is Rhopressa a public company?
Rhopressa is private company therefore does not currently have an official ticker symbol
See more information about Rhopressa

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.